MetaCap

Celularity (CELU) vs Context Therapeutics (CNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Celularity (CELU) has outperformed Context Therapeutics (CNTX) over the past year, losing 73.5% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -99.3% for CELU. Celularity is the larger company by market cap ($15.0 million vs $14.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELU-73.54%CNTX-85.32%
+223%+61%-100%
Nov 21, 20251 yearNov 20, 2026
CELU-99.34%CNTX-96.73%
+83%-12%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELU versus CNTX key metrics
MetricCELUCNTX
Share price$0.463$0.16
Market cap$15.02M$14.70M
1-day change-1.05%-5.10%
YTD return-58.29%-89.12%
1-year return-73.54%-85.32%
5-year return-99.31%-96.86%
EPS (TTM)$-1.69$-0.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$26.55M—
Revenue growth (YoY)-51.03%—
Net income (latest FY)$-91.72M$-36.12M
Gross margin24.39%—
Operating margin-230.92%—
Net margin-345.45%—
52-week high$2.55$3.62
52-week low$0.42$0.153
Distance from 52-week high-81.84%-95.58%
Analyst consensus—none
Avg. price target upside—+2418.75%
Average volume3.95M1.42M
Shares outstanding32.45M91.88M
Employees11515
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CELU has outperformed CNTX by 11.8 percentage points over the past year.

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

About Context Therapeutics

CNTX stock →

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

CELU vs CNTX FAQ

Which is bigger, Celularity or Context Therapeutics?

Celularity (CELU) is larger, with a market capitalization of $15.02M compared with $14.70M for Context Therapeutics (CNTX).

Which stock has performed better over the past year, CELU or CNTX?

CELU returned -73.54% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.

Are Celularity and Context Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons